The snow is falling, clinics are cancelled, staff is scrambling to call patients for reappointments, and coordinators are rebooking research participants due to the storm. . .but the snow is a spectacular sight, just fallen and deep. A break in the usual hectic pace offers that moment to reflect.
We’re busy with Society issues, but looking forward to the annual meeting in Chicago in May. A record number of abstracts have been submitted for presentation at the meeting, the Discovery program is robust, and things continue to shape up for an exciting gathering. The continued commitment of both researchers and the clinically engaged members of the society is evident. The awards committee was impressed with the high quality of the grant applications for the Research Fellowship, Clinical Scholar, and EDI awards. The committees are busy at all levels.
This month I am highlighting the Publications Committee, headed by Colin Hawkes, at Cork University in Ireland.
Colin Hawkes
One of the major functions of the Publications Committee is serving as the Society’s liaison with Hormone Research in Paediatrics, our Society-sponsored journal. The committee is engaged with the management of the society’s member composition of the journal’s Editorial Board. Colin and Stefano Cianfarani, the Editor-in-Chief, have recently formalized a policy for appointments to the board, emphasizing the involvement of younger members in this role. The Publications Committee will initiate a call for interested participants at the annual meeting. Thanks to Colin and the committee for this important work.
NIH supporting Child Care Costs:
- DID you KNOW: An NIH policy provides up to $2,500 in childcare cost support to full-time National Research Service Award (NRSA) fellows and trainees. In fact, childcare support was approved for nearly every researcher awarded an NRSA fellowship who requested support. The total number of childcare awards rose from 231 in FY 2021 to 331 in FY 2023, and the percentage of fellows that received this support rose from 5.6% to 8.4% over this time.
See:
https://grants.nih.gov/grants/policy/nih-family-friendly-initiative.htm
Best,
Tom Carpenter, MD
The Honors and Lectures Committee is pleased to announce the 2024 PES Award Winners, Congratulations!
- Judson J. Van Wyk Prize – Morey Haymond, MD
- Del and Beverly Fisher Pediatric Endocrinology History Lectureship – Stephen LaFranchi, MD
- Young Investigator Award – Shylaja Srinivasan, MD
- Clinician Award – Don Wilson, MD
- Educator Award – Marco Danon, MD
- Senior Investigator Award – Stephen Gitelman, MD
- 2024 Mentor of the Year Award – Rose A. Gubitosi-Klug, MD, PhD
2024 Annual Meeting Registration
Registration is officially open for our 2024 Annual Meeting, happening exclusively in person from May 2-5, 2024, in Chicago, IL. Don’t miss out on this information-packed event!
Programming this year will delve into cutting-edge scientific insights, featuring symposia, spark sessions, year in reviews, meet the professors, 200+ posters, 3 oral abstract sessions and more. This is sure to be the best Annual Meeting yet. Explore the conference program overview here, and more details will be coming your way soon!
The early bird gets the discount! Take advantage of early bird pricing by registering today– it’s an unbeatable deal, but only for a limited time. Early bird registration rates are available through March 10, 2024 and hotel rooms are going fast! Do not delay-Secure your spot now.
Register here: https://pedsendo.us19.list-manage.com/track/click?u=c2f9ca8dede570897812773d0&id=a2c32f0df5&e=3130efeb26
2024 Travel Grants Now Open
PES is pleased to offer Fellows presenting at the PES Annual Meeting the opportunity to win Travel Grants.
Eligible applicants fall under the following categories:
- Applicants are eligible if they are a fellow in April 2024 and if they are PES member at the time they apply.
- They have had an abstract accepted for oral or poster presentation at PES.
- They have no other external source of travel funding.
- Applicants meeting these criteria will be entered into a random drawing (number of grants and the amount TBD)
Successful applicants will be notified of award after the abstract selections have been communicated.
Deadline: Friday, March 29, 2024
Apply here: https://pedsendo.org/2024-travel-grant-application/
Sogroya® (somapacitan-beco) Injection 15mg Pen Supply Update
From: Novo Nordisk (mail@communications.novonordisk.com)
Due to higher than anticipated demand, Novo Nordisk will be unable to provide the Sogroya 15 mg pen from Mid-February through May 2024. However, there is an ample supply of the 5mg and 10mg pens to address total Sogroya® demand and as a solution for patients who would otherwise use the 15mg pen.
New resources and tools are available to help determine strength and # of pens to prescribe, based on a patient’s weekly dose, including the Pen Selector Tool, live on www.sogroyapro.com.
Click here to read more: https://pedsendo.org/drug-shortages/sogroya-somapacitan-beco-injection-15mg-pen-supply-update/
Recall of Baby’s Vitamin D3 Liquid by Nordic Naturals due to Elevated Levels of Vitamin D3
Nordic Naturals is recalling one lot (#234909, expiration date of 12/2025) of Nordic Naturals Baby’s Vitamin D3 Liquid, 400 IU (10 mcg). This recall is being conducted due to a manufacturing error that resulted in an elevated level of vitamin D3 concentration increasing risk of a potential vitamin D3 toxicity. For more information and reporting of adverse events, visit Nordic Naturals Issues Voluntary Recall of Baby’s Vitamin D3 Liquid Due to Elevated Levels of Vitamin D3 | FDA.
From the D&T Committee: US FDA-approval of VAMOROLONE for Duchenne Muscular Dystrophy (DMD)*-a novel alternative steroid with unique properties
On October 26, 2023, the US Food and Drug Administration (FDA) approved AGAMREE (Vamorolone/VBP 15) 6 mg/kg/day for the treatment of Duchenne Muscular Dystrophy (DMD) for patients 2 years of age and older.1 [Catalyst Pharmaceuticals, Coral Gables, Fl.; developed by Santhera Pharmaceuticals (Pratteln, Switzerland www.santhera.com)].
AGAMREE (Vamorolone) is a first-in-class oral medication, that is a novel alternative steroid that binds to the same receptors as corticosteroids and modifies their downstream activity.2,3
Pediatrics Supplement: A Workforce Projection Model
This month’s Pediatrics Supplement presents a workforce projection model that estimates the future supply of pediatric subspecialists from 2020-2040. Current trends for the pediatric endocrinology workforce in the US show that it is struggling to sustain an adequate, let alone optimal, workforce capacity. The article reviews the current state of the workforce and presents projected headcount and clinical workforce equivalents at the national, census region, and census division level on the basis of a subspecialty workforce supply model through 2040. It concludes by discussing the educational and training, clinical practice, policy, and future workforce research implications of the data presented.
Those who cannot access the journal can go to: https://www.abp.org/content/projecting-future-us-pediatric-subspecialty-workforce where there is a 4 min overview video as well as a link to the paper.
New Meds and Tech – LUPRON DEPOT-PED 45 mg for 6 months
Prepared and edited on behalf of the PES Drug & Therapeutics committee: Shilpa Mehta, MD, Amit Lahoti, MD, Aditi Khokar, MD, Anna Ryabets-Lienhard, DO, and Ryan Miller, MD
LUPRON DEPOT-PED® (leuprolide acetate for depot suspension) 45 mg for 6-month intramuscular injection is a GnRH analog (GnRHa) approved as a treatment for children with central precocious puberty (CPP). It has the same administration and features as 3-month and 1-month Lupron doses (prefilled dual chamber syringe along with Lupraloc safety technology/ 23-gauge 1.5-inch needle and injection volume of 1.5 ml; no refrigeration is required). Injection site reactions were the most common side effect. No head-to-head comparison studies with other GnRHa preparations are available to compare outcomes at this time. Read more: https://pedsendo.org/new-meds-and-tech/lupron-depot-ped-45-mg-for-6-months/
Online Education in March: Save the dates!
Our spring lineup of educational webinars are headed your direction! Save the dates and keep an eye out for additional information here: Events – Pediatric Endocrine Society (pedsendo.org) #LearningAdventure #OnlineLearning #EducationalWebinars
Historical Tidbit: Téophile de Bordeu (1722-1776): Incretory Activity and the Foundations of Endocrinology
Submitted by Alan Rogol, MD
Fellow Spotlight – Imen Becetti, MD
Meet Imen: February Fellow Spotlight – Imen Becetti, MD – Pediatric Endocrine Society (pedsendo.org)
EDI Spotlight: The Articles of Confederation
Authored by: Ambika Ashraf and Ilene Fennoy
The Articles of Confederation, ratified by all thirteen states on March 1, 1781, marked a seminal moment in American history, serving as the United States’ first constitution. Although the Articles themselves were replaced by the current U.S. Constitution in 1789, they have had a lasting influence on the political landscape of today in several key areas of American political thought, governance, and federal-state relations. Learn more: Equity, Diversity and Inclusion Initiative – Pediatric Endocrine Society (pedsendo.org)
The post February 2024 President’s Letter first appeared on Pediatric Endocrine Society.
The post February 2024 President’s Letter appeared first on Pediatric Endocrine Society.
